{"id":556684,"date":"2026-05-30T12:30:00","date_gmt":"2026-05-30T10:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=556684"},"modified":"2026-05-30T13:48:57","modified_gmt":"2026-05-30T11:48:57","slug":"options-therapeutiques-immunologiques-et-ciblees-niveau-de-preuve-2025-2026","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/options-therapeutiques-immunologiques-et-ciblees-niveau-de-preuve-2025-2026\/","title":{"rendered":"Options th\u00e9rapeutiques immunologiques et cibl\u00e9es : Niveau de preuve 2025\/2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Le traitement du carcinome uroth\u00e9lial a consid\u00e9rablement \u00e9volu\u00e9 au cours des derni\u00e8res ann\u00e9es. Les immunoth\u00e9rapies modernes, les conjugu\u00e9s anticorps-m\u00e9dicament (ADC) et les substances cibl\u00e9es compl\u00e8tent les chimioth\u00e9rapies classiques et permettent de plus en plus des strat\u00e9gies de traitement individualis\u00e9es. De nouvelles donn\u00e9es de 2025 et 2026 montrent que les th\u00e9rapies combin\u00e9es, les concepts de maintenance et les approches bas\u00e9es sur les biomarqueurs, en particulier, gagnent en importance. De plus, la planification moderne des traitements b\u00e9n\u00e9ficie d&#8217;un diagnostic plus pr\u00e9cis.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Foptions-therapeutiques-immunologiques-et-ciblees-niveau-de-preuve-2025-2026%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Le traitement du carcinome uroth\u00e9lial a consid\u00e9rablement \u00e9volu\u00e9 au cours des derni\u00e8res ann\u00e9es. Les immunoth\u00e9rapies modernes, les conjugu\u00e9s anticorps-m\u00e9dicament (ADC) et les substances cibl\u00e9es compl\u00e8tent les chimioth\u00e9rapies classiques et permettent&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Foptions-therapeutiques-immunologiques-et-ciblees-niveau-de-preuve-2025-2026%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":556686,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Carcinome uroth\u00e9lial ","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11549,11527,11531,11389,11514],"tags":[92630,92648,92638,92634,49942,92629,92653,18813,17611,92636,90033,92637,92646,92628,92643,92644,92650,92652,92647,67206,92645,26529,92642,78128,92641,92651,92640,15801,92623,92639,92633,92622,90848,92626,17044,92627,92624,92632,92625,92631,92635],"powerkit_post_featured":[],"class_list":["post-556684","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-etudes","category-formation-continue","category-oncologie","category-urologie-fr","tag-analyse-du-score-de-propension","tag-anticorps-substance-active-conjugues","tag-association-durvalumab","tag-aumonier-meier-pfs-os","tag-biologie-des-tumeurs","tag-bl-b01d1","tag-cancer-de-lappareil-urinaire","tag-carcinome-de-la-vessie","tag-carcinome-urothelial","tag-carcinome-urothelial-metastatique","tag-chimiotherapie-a-base-de-platine","tag-chimiotherapie-neoadjuvante","tag-combinaison-de-carboplatine","tag-disitamab-vedotin","tag-enfortumab-vedotin","tag-evp","tag-expression-de-her2","tag-expression-de-la-nectine-4","tag-gemcitabine-cisplatine","tag-imagerie-fonctionnelle","tag-immunotherapie-urotheliale","tag-inhibiteurs-de-points-de-controle-immunitaires","tag-javelin-bladder100","tag-les-tumorboards-interdisciplinaires","tag-maintien-de-lavelumab","tag-mutation-fgfr3","tag-nectin-4-pet","tag-pembrolizumab-fr","tag-pet-ct-capacites-suisse","tag-pet-ct-pronostic","tag-preuve-du-monde-reel-evp","tag-systeme-de-sante-suisse-oncologie","tag-therapie-adc","tag-therapie-basee-sur-les-biomarqueurs","tag-therapie-ciblee","tag-therapie-ciblee-sur-le-fgfr","tag-therapie-sequentielle-de-lurothelium","tag-toripalimab","tag-traitement-cible-sur-her2","tag-traitement-de-deuxieme-intention-de-lurothelium","tag-traitement-de-premiere-ligne-de-lurothelium","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-08-23 15:38:51","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":556681,"slug":"opzioni-di-terapia-immunitaria-e-mirata-situazione-delle-evidenze-2025-2026","post_title":"Opzioni di terapia immunitaria e mirata: Situazione delle evidenze 2025\/2026","href":"https:\/\/medizinonline.com\/it\/opzioni-di-terapia-immunitaria-e-mirata-situazione-delle-evidenze-2025-2026\/"},"pt_PT":{"locale":"pt_PT","id":556685,"slug":"opcoes-de-terapia-imune-e-direcionada-situacao-da-evidencia-2025-2026","post_title":"Op\u00e7\u00f5es de terapia imune e direcionada: Situa\u00e7\u00e3o da evid\u00eancia 2025\/2026","href":"https:\/\/medizinonline.com\/pt-pt\/opcoes-de-terapia-imune-e-direcionada-situacao-da-evidencia-2025-2026\/"},"es_ES":{"locale":"es_ES","id":556678,"slug":"opciones-de-terapia-inmunologica-y-dirigida-situacion-de-las-pruebas-2025-2026","post_title":"Opciones de terapia inmunol\u00f3gica y dirigida: Situaci\u00f3n de las pruebas 2025\/2026","href":"https:\/\/medizinonline.com\/es\/opciones-de-terapia-inmunologica-y-dirigida-situacion-de-las-pruebas-2025-2026\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/556684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=556684"}],"version-history":[{"count":3,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/556684\/revisions"}],"predecessor-version":[{"id":556692,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/556684\/revisions\/556692"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/556686"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=556684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=556684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=556684"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=556684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}